gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ACRSHealthcarePharmaceuticals

Aclaris Therapeutics, Inc. (ACRS)

$3.68−1.60%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$3.77▲ 47.46% in range
Nov 3, 2025Low $2.13 · High $6.54Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Aclaris Therapeutics closed at $3.68 on Nov 4, down 1.60%, 43.7% below its 52-week closing high. Volume of 2.0M shares was 0.58× its 20-day average (below normal).

Split-adjusted performance: -0.5% over one month, -23.0% over six months, +43.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.63M, down 8.3% from a year earlier, with a net margin of -1320.1%.

Short interest was 15.0M shares at the Oct 15 settlement, down 17.4% from the prior report (12.4% of float, 3.0 days to cover).

Market cap$570.3M155.0M shares
Revenue · quarter$1.6M−8.3% YoY
Diluted EPS$-0.15—
P/E · TTM—P/S 69.4×
Net margin-1,320.1%Gross 86.6%
Dividend yieldNone
52-week range2.13 – 6.54−43.7% from high
Volume2.0M0.58× 20-day avg
Volatility · 60d75.7%Annualised
Short % of float12.4%3.0 days to cover
Net cash$91.6MCash $91.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.1%1M −0.5%3M −39.6%6M −23.0%YTD +22.3%1Y +43.8%3Y −19.7%5Y −77.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum54
Revenue growth34
Net margin18
Value (low P/E)—
Size63

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short15.0M−17.4% vs prior
Days to cover3.0Settled Oct 15
% of float12.4%
Short vol. 10d54.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ACRSAclaris Therapeutics$3.68−1.60%−23.0%−8.3%−1320.1%—$570.3M
DMACDiaMedica Therapeutics$10.77+7.70%+65.2%———$580.8MCompare
BCAXBicara Therapeutics$8.89−0.78%−62.6%———$588.3MCompare
NGNENeurogene$27.58+3.41%−14.7%———$551.9MCompare
PBYIPUMA BIOTECHNOLOGY$10.69+4.60%+43.5%+7.8%14.5%20.7$551.8MCompare
NVCTNuvectis Pharma$18.47−4.50%+84.7%———$602.9MCompare
CLYMClimb Bio$9.33−4.31%−23.6%———$535.9MCompare
OVIDOvid Therapeutics$2.74+14.17%−1.4%−88.3%−2047.6%—$535.1MCompare
IRWDIronwood Pharmaceuticals, Inc. -$3.77+7.71%−21.9%+32.6%45.4%4.8$623.0MCompare

News about Aclaris Therapeutics

All news →
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and AsthmaGlobeNewswire Inc. · Oct 27, 2026▲ PositiveAclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferenceGlobeNewswire Inc. · Sep 3, 2026NeutralAclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual MeetingGlobeNewswire Inc. · Mar 20, 2026▲ Positive

Quick answers

What does Aclaris Therapeutics do?
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform.
What is ACRS's market cap?
$570.34M, based on the Nov 4 close of $3.68.
Does Aclaris Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ACRS is sold short?
15.0M shares, 12.4% of float, as of Oct 15, 2026.
What sector is ACRS in?
Healthcare, in the Pharmaceuticals industry.

About Aclaris Therapeutics

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

HQ: Wayne, PA73 employeesListed Oct 7, 2015aclaristx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology